Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    Kansas HCC sorafenib
Show Display Options
Rank Status Study
1 Active, not recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
2 Active, not recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Conditions: Hepatocellular Carcinoma;   Non-Resectable Hepatocellular Carcinoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Doxorubicin-Eluting Beads;   Other: Laboratory Biomarker Analysis;   Drug: Mitomycin;   Other: Pharmacological Study;   Other: Placebo;   Drug: Sorafenib Tosylate
3 Completed
Has Results
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
4 Active, not recruiting Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Adult Hepatocellular Carcinoma
Intervention: Drug: Dalantercept plus sorafenib
5 Completed Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Condition: Liver Cancer
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate
6 Active, not recruiting A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Drug: Lenvatinib;   Drug: Sorafenib
7 Completed Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
8 Active, not recruiting
Has Results
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
9 Active, not recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
10 Completed
Has Results
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Placebo tablets
12 Completed
Has Results
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Condition: Carcinoma
Interventions: Drug: Everolimus;   Drug: Everolimus Placebo;   Other: Best Supportive Care (BSC)
13 Withdrawn Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: INC280;   Drug: Placebo
14 Recruiting Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Conditions: Brain Tumor;   Glioblastoma;   Anaplastic Glioma
Interventions: Drug: everolimus;   Drug: sorafenib
15 Completed
Has Results
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib;   Drug: Sorafenib

Indicates status has not been verified in more than two years